Four with Medical School ties are among 12 University of Michigan faculty and staff members recognized by the American Association for the Advancement of Science (AAAS) as 2023 fellows in recognition of their extraordinary achievements.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

A study from clinicians and researchers at the University of Michigan Rogel Cancer Center reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.

There are 13 U-M graduate medical education programs ranked in the top 10 by Doximity.

An interview with Dr. Steven Kunkel on research at U-M Medical School.

Gene therapy for hemophilia B, a rare bleeding disorder, reinforces lower bleeding rates and improved outcomes.

Russell Ryan, MD, and his team’s discovery appears to address longstanding mysteries about mutations found in B-cell acute lymphoblastic leukemia

The American Association for the Advancement of Science elected 17 University of Michigan faculty and staff members as 2022 Fellows.

For some patients, immunotherapy furthers tumor progression instead of halting it. What distinguishes those who benefit from those who don’t?

Michigan Medicine experts share how their work is contributing to gender-affirming and other forms of equitable health care for the LGBTQ+ community.